Skip to main content

Table 1 Analysis of occurrence events for genes in the ovarian cancer prognostic gene signature set.

From: Multiple signatures of a disease in potential biomarker space: Getting the signatures consensus and identification of novel biomarkers

#Number of
signatures with gene
*Expected
Percentage
(100 simulations)
Actual
Percentage
Enrichment
(actual/expected)
Number of genes
from our signature
Genes from our signature
0 80.89 52.78 0.65 19 POLA2, NCAPG2, PLAUR, FZD1, CCT2, DNMT1, PIK3R1, POLR2J, TGFBR2, VCL, NCAPD2, POLR2D, HGF, FGFR1, MIS12, ARPC1B, CD93, CDK4, NCAPH
1 17.14 13.89 0.81 5 MMP13, CBX3, CHEK1, LAMA4, TCP1
2 1.89 19.44 10.29 7 CDC6, CAV2, GNG12, CD44, MCM2, CALD1, CFD
3 0.08 5.56 66.67 2 CCL2, PDGFRA
4 0.00 2.78 Not applicable 1 TUBB
5 0.00 2.78 Not applicable 1 EDNRA
6 0.00 2.78 Not applicable 1 COL3A1
  1. Expected and actual frequency of co-occurrences of 36 genes in our prognostic signature with 60 other reference gene signature subsets. All signatures are ovarian cancer-related.
  2. *The expected percentage from 1000 and 10000 simulations can be found in Additional file 3.